A detailed history of New Edge Advisors, LLC transactions in Alkermes Plc. stock. As of the latest transaction made, New Edge Advisors, LLC holds 57 shares of ALKS stock, worth $1,796. This represents 0.0% of its overall portfolio holdings.

Number of Shares
57
Previous 57 -0.0%
Holding current value
$1,796
Previous $1,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 15, 2024

SELL
$23.21 - $27.24 $311,826 - $365,969
-13,435 Reduced 99.58%
57 $1,000
Q1 2024

May 14, 2024

SELL
$26.4 - $32.56 $51,084 - $63,003
-1,935 Reduced 12.54%
13,492 $365,000
Q4 2023

Feb 13, 2024

SELL
$23.37 - $28.68 $162,304 - $199,182
-6,945 Reduced 31.04%
15,427 $427,000
Q3 2023

Nov 14, 2023

BUY
$27.17 - $31.97 $607,847 - $715,232
22,372 New
22,372 $626,000
Q4 2022

Feb 14, 2023

BUY
$21.94 - $26.24 $3,356 - $4,014
153 New
153 $3,000
Q3 2017

Nov 13, 2017

SELL
$49.16 - $54.45 $8,357 - $9,256
-170 Closed
0 $0
Q2 2017

Aug 16, 2017

BUY
N/A
170
170 $0

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $5.18B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track New Edge Advisors, LLC Portfolio

Follow New Edge Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.